Gibson Christopher 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Recursion Pharmaceuticals (RXRX) Director Christopher Gibson Sells 40,000 Shares
What Happened
Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), disposed of 40,000 shares on June 5, 2026. The shares were converted automatically from Class B common stock into Class A common stock (no cash paid on conversion) and then sold in the open market at $3.62 per share for proceeds of $144,800.
Key Details
- Transaction date: June 5, 2026. Sale price: $3.62 per share; total proceeds: $144,800.
- Conversion: 40,000 Class B shares converted into 40,000 Class A shares (automatic conversion in connection with the sale). Each Class B converts 1:1 to Class A.
- The sale was executed pursuant to a Rule 10b5‑1 trading plan (adopted May 12, 2025).
- The filing does not state Gibson’s total shares owned after this transaction in the provided excerpt.
- No indication in this report that the Form 4 was filed late.
Context
This was effectively a conversion-plus-sale (the converted shares were immediately sold), not a new cash purchase — a routine liquidity event rather than a clear bullish purchase signal. Conversions of Class B to Class A are mechanical (each Class B is convertible into one Class A) and the sale under a 10b5‑1 plan indicates pre‑scheduled trading.
Insider Transaction Report
- Conversion
Class A Common Stock
[F1][F2]2026-06-05+40,000→ 923,735 total - Sale
Class A Common Stock
[F2]2026-06-05$3.62/sh−40,000$144,800→ 883,735 total - Conversion
Class B Common Stock
[F3][F1][F2]2026-06-05−40,000→ 4,263,334 totalExercise: $0.00→ Class A Common Stock (40,000 underlying)
- 386,000(indirect: By LLC)
Class B Common Stock
[F3][F4]Exercise: $0.00→ Class A Common Stock (0 underlying) - 388,000(indirect: By LLC)
Class B Common Stock
[F3][F5]Exercise: $0.00→ Class A Common Stock (0 underlying) - 50,000(indirect: By Trust)
Class B Common Stock
[F3][F6]Exercise: $0.00→ Class A Common Stock (0 underlying) - 1,050,567
Stock Option (Right to Buy)
[F7]Exercise: $7.25Exp: 2035-02-03→ Class A Common Stock (0 underlying) - 666,898
Stock Option (Right to Buy)
[F8]Exercise: $10.09Exp: 2034-02-09→ Class A Common Stock (0 underlying) - 813,600
Stock Option (Right to Buy)
[F9]Exercise: $8.55Exp: 2033-02-01→ Class A Common Stock (0 underlying) - 399,002
Stock Option (Right to Buy)
[F10]Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 5,436
Stock Option (Right to Buy)
Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 282,500
Stock Option (Right to Buy)
[F11]Exercise: $2.48Exp: 2030-12-30→ Class A Common Stock (0 underlying)
Footnotes (11)
- [F1]Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock.
- [F10]The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F11]The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- [F2]This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
- [F3]Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
- [F4]The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
- [F5]The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
- [F6]The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
- [F7]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F8]The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F9]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.